HTS Classification for Pharmaceutical Products: APIs, Formulations, Medical Devices, and Biologics

The Intersection of Trade and Pharma Regulation

Pharmaceutical products represent one of the most heavily regulated import categories in the United States, and HTS classification is only the beginning. Every pharmaceutical shipment must satisfy requirements from the FDA, DEA (for controlled substances), and CBP simultaneously. Getting the HTS classification right matters not only for duty purposes but because it triggers different regulatory review pathways. A product classified as a medicament under Chapter 30 faces different entry requirements than the same active ingredient classified as a bulk chemical under Chapters 28 or 29. The United States imports over $200 billion in pharmaceutical products annually, and the tariff landscape for these products is complex — many are duty-free, but others face significant duty rates depending on their exact classification and country of origin.

Chapter 30: Pharmaceutical Products

Chapter 30 of the HTS covers pharmaceutical products, but the scope is narrower than many importers assume. Heading 3001 covers glands and other organs for organotherapeutic uses, extracts thereof, and other human or animal substances prepared for therapeutic use. Heading 3002 covers human blood, animal blood for therapeutic uses, antisera, vaccines, toxins, and cultures of micro-organisms — this is where most biologics, including monoclonal antibodies and therapeutic proteins, are classified. Heading 3003 covers medicaments consisting of two or more constituents mixed together, NOT put up in measured doses or for retail sale. Heading 3004 covers medicaments put up in measured doses or in forms or packings for retail sale. Heading 3005 covers wadding, gauze, bandages, and similar articles with pharmaceutical substances for medical use. Heading 3006 covers pharmaceutical goods such as sterile surgical catgut, blood-grouping reagents, dental cements, and first-aid kits.

Active Pharmaceutical Ingredients (APIs) and Chemical Classification

Bulk APIs are classified based on their chemical identity, not their intended pharmaceutical use. A pure organic compound used as an API classifies under Chapter 29, in the heading that corresponds to its chemical structure. For example, paracetamol (acetaminophen) as a bulk powder classifies under 2924.29 (cyclic amides). Ibuprofen classifies under 2916.39 (aromatic monocarboxylic acids). Antibiotics such as amoxicillin classify under heading 2941. Vitamins and provitamins classify under heading 2936. Hormones classify under heading 2937. Alkaloids and their derivatives fall under headings 2939-2940. The classification can become complex when an API does not fit neatly into a defined chemical heading, in which case it may fall into residual headings like 2942 (other organic compounds). Once an API is mixed with excipients — binders, fillers, disintegrants, coatings — the resulting formulation is classified under Chapter 30.

• Bulk organic APIs (pure compounds): Chapter 29, classified by chemical structure
• Bulk inorganic APIs: Chapter 28
• Antibiotics in bulk: 2941
• Vitamins in bulk: 2936
• Hormones in bulk: 2937
• Formulated drugs (mixed, not in doses): 3003
• Finished dosage forms (tablets, capsules, injectables): 3004
• Vaccines and blood products: 3002
• Diagnostic reagents: 3002.90 or 3822

Biologics, Vaccines, and Gene Therapies

Biological products are increasingly important in pharmaceutical trade. Vaccines classify under 3002.20. Monoclonal antibodies and other immunological products classify under 3002.13-3002.15. Human blood and blood components classify under 3002.90. Gene therapy products and cell-based therapies present emerging classification challenges. CBP has generally classified gene therapy vectors under 3002 when they are products of micro-organism culture, but the classification of novel modalities like mRNA therapeutics, CRISPR-based treatments, and CAR-T cell products continues to evolve. Importers of biologics should pay particular attention to cold-chain requirements that may affect the declared value and the mode of transport, both of which interact with customs entry requirements.

Medical Devices: Chapter 90 and Beyond

Medical devices do not classify under Chapter 30 — they are primarily found in Chapter 90 (Optical, Photographic, Measuring, Medical Instruments). Heading 9018 covers instruments and appliances used in medical, surgical, dental, or veterinary sciences — this includes syringes, needles, catheters, surgical instruments, and electromedical apparatus. Heading 9019 covers mechano-therapy appliances, massage apparatus, and breathing apparatus. Heading 9021 covers orthopedic appliances, artificial joints, hearing aids, and pacemakers. Heading 9022 covers apparatus based on X-rays or radiation. In vitro diagnostic devices may classify under 9027 (instruments for physical or chemical analysis) or 3822 (diagnostic or laboratory reagents). Combination products that include both a device and a drug component — such as a drug-eluting stent or a pre-filled syringe — must be classified according to the component that gives the product its essential character under GRI 3(b).

Duty-Free Benefits and Trade Agreements

Many pharmaceutical products enter the United States duty-free under the WTO Pharmaceutical Agreement (also known as the 'Pharma Appendix'). This agreement eliminates tariffs on a defined list of pharmaceutical products identified by their International Nonproprietary Name (INN). However, eligibility depends on the product being classified correctly — an API that qualifies for zero duty under the Pharma Appendix when classified in Chapter 29 might not qualify if incorrectly classified under a different heading. Not all pharmaceutical products are covered; the list is periodically updated, and newer drug substances may not yet be included. Excipients, packaging materials, and manufacturing equipment do not benefit from the Pharma Appendix and are subject to normal duty rates. Additionally, certain products from specific countries may face Section 301 tariffs regardless of their pharmaceutical nature.

Common Pitfalls in Pharmaceutical Classification

1. Classifying bulk APIs under Chapter 30: Pure chemical compounds belong in Chapters 28 or 29, even when destined for pharmaceutical manufacturing.
2. Ignoring the dosage form distinction: 3003 (not in doses) versus 3004 (in doses or retail packing) — this distinction affects both duty rates and FDA regulatory treatment.
3. Misclassifying dietary supplements as medicaments: Products marketed as dietary supplements may not qualify as 'medicaments' under Chapter 30 and often classify under 2106 (food preparations) or Chapter 29.
4. Confusing medical devices with pharmaceutical products: Devices classify under Chapter 90, not Chapter 30, even when used in drug delivery.
5. Overlooking the Pharma Appendix: Failing to claim duty-free treatment for eligible products costs importers millions in unnecessary duties annually.
6. Mishandling combination products: Drug-device combinations require careful GRI analysis to determine essential character.

“The classification of pharmaceutical products requires an understanding not only of the tariff schedule but also of chemistry, pharmacology, and manufacturing processes. The tariff does not care what a product is intended to do — it cares what the product is.”

— CBP Informed Compliance Publication on Pharmaceuticals